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Chelating Agents and Cadmium Toxicity:
Problems and Prospecs
by Gunnar F. Nordberg*
Symptoms and signs in humans after excessive exposure to cadmium usually involve
the gastrointestinal tract after single oral intake, the lung after acute inhalation, and the
kidney afterlong-term exposure. These organs areusually consideredto be the "critical"
organs,i.e.,theorgansmostsensitive atacertaintypeofexposure.Thetype ofCd-related
damage that is most common in humans is probably the renal toxicity after long-term
exposure. Most animal experiments, including the most recently published ones, have
involvedstudyofgrosstoxicity andtissue distributionafterin ectionofcadmium inacute
experiments. The observations in the older literature that the influence of chelating
agents on Cd distribution and excretion is confined to the early period after acute Cd
exposure has been confirmed and extended, and the relationship to the time course of
metallothionein synthesis has been demonstrated. Although the injection experiments
concerning cadmium distribution, particularly those employing repeated exposure, may
furnish information that can form a basis for speculation about long-term toxicity to the
kidney, there is a lack of direct studies in animals of possible beneficial effects of
chelating agents on renal toxicity ofcadmium after prolonged exposure. Among the few
studies reported, either anincreasedrenaltoxicity or alackofinfluence on renaltoxicity
hasbeenobserved. Theproblems infindingatreatment scheme thatcanbebeneficial for
the renaltoxicity resulting from long-term cadmium exposure thus remain; however, the
prospects of finding such schemes in the future seem favorable in view of some of the
recent observations.
Introduction
The toxicology of cadmium has attracted con-
siderable interest during a number of years be-
cause ofthe cumulativeproperties ofthis element
and the identification of its potential health im-
pacts, particularly those related to long-term ac-
cumulation and subsequent damage to the kid-
ney. Thekidney is consideredto bethe organthat
is most sensitive to long-term exposure to cad-
mium, i.e., the critical organ for this type of
exposure. Althoughthistype ofcadmium-induced
damage does not frequently occur in the general
population, ahigh incidence has been reported in
some population groups in areas where food and
drinkingwaterhavebeencontaminatedwithcad-
mium. Also, among industrial workers (1) who
have beenexposed to cadmium for longperiods of
time,renaldysfunction may occur. Early stagesof
such renal dysfunction are not associated with
any serious clinical complaints, except possibly a
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higher incidence ofrenal stones.
The management ofsuchcasesusually doesnot
require the use of drugs, but only removal of
further exposure. Major clinical symptoms ofre-
nal disease are usually not seen. However, since
the renal tubular dysfunction usually persists for
many years, it would be desirable to have access
to possibilities to treat this dysfunction. A safe
drug without side effects would be required for
that purpose. However, efforts made in the 1940s
and 1950s to find such a drugwere disappointing,
and it has been customary not to advocate treat-
ment ofthese types ofcases. In the present paper
the more important features ofcadmium poison-
ing will be given, and the current evidence con-
cerninginfluenceofchelatingagentsoncadmium
turnover and toxicity will be discussed.
Features of Cadmium Poisoning
in Man and Experimental Animals
After a single injection (intravenously or inter-
peritoneally) ofsoluble cadmium salts into exper-G. NORDBERG
imental animals, a number of lesions in various
organs may occur (1). At sufficiently high doses,
liver necrosis, necrosis of sensory ganglia and
testicular necrosis (in male animals) or placental
necrosis (inpregnant animals) isobserved. Lethal
effects are related to the liver necrosis, but testic-
ular necrosis, for example, can be induced at
considerably lower injected doses that do not give
rise to damage to other organs. The testicles thus
are to be regarded as the critical organ (in preg-
nant animals, probably the placenta). However,
in acute toxicity experiments, where only mortal-
ity is recorded, the effects ofcadmium onthe liver
may be the most important effect.
After short-term oral exposure, the type of
damage that will be induced is to some extent
dependent on the animal species. Whereas the
vomiting reflex is quickly induced in humans at
relatively limited concentrations of cadmium in
ingested food or drink (about 15 mg/L), rats, for
example, may tolerate much larger concentra-
tions without such gastrointestinal reactions. In
the latter species, therefore, both liver necrosis
and other lesions may be observed after such
exposure, whereas the gastrointestinal reactions
are dominant in man. The gastrointestinal effect
can be regarded as the critical effect in acute oral
exposures.
After short-term inhalation, the lung damage
is predominant; the lung may be regarded as the
critical organ.
As discussed previously, long-term exposure to
cadmium gives rise primarily to renal tubular
proteinuria regardless of whether exposure is
oral, by inhalation or by means ofrepeated long-
term injection. However, lung damage may also
occur in the long-term inhalation situation, i.e.,
when sufficiently high concentrations ofcadmium
are inhaled. When lower concentrations are in-
haled during longer periods of times, lung dam-
age is lessprominent, andrenal tubularproteinu-
ria dominates. Recently ithas been demonstrated
in animals that even rather low concentrations of
cadmium in air may give rise to lung cancer (2).
However, usually the kidneys are considered as
the critical organ. The lung cancer might well
turn out to be the critical effect, in future evalua-
tions.
Cadmium Chelation by
Metallothionein
Cadmium chelation by metallothionein and its
relationship to cadmium toxicity was originally
suggested by Piscator (3) and Nordberg (4,5) and
further reviewed by Andersen (6). A few general
aspects will be mentioned here. The deleterious
effects of cadmium are due to binding at the
sensitive site in the cell, i.e., metallothionein-
cadmium or other types of cadmium chelates
would be considered inactive. However, metal-
lothionein-cadmium and chelate cadmium un-
dergo breakdown in the tissues, and nonchelated
cadmium may be released. When the tissue con-
centration ofnonchelated cadmium exceeds a cer-
tain level, toxicity occurs in the tissue. This is
important to remember when discussing effects of
chelating agents on cadmium toxicity.
Chelating Agents and Cadmium
Toxicity
This review will not attempt to be complete but
will take up some ofthe more important evidence
available concerning effects of chelating agents
on cadmium toxicity. In 1946, Gilman et al. (7)
documented a decrease in the acute mortality
normally incurred after a single injection ofcad-
mium when rabbits were treated with 2,3-dimer-
captopropanol (BAL). However, several of the
rabbits succumbed later from kidney damage. In
a follow-up of these studies, Tepperman (8)
showed that BAL increased the uptake of cad-
mium in the kidneys, an observation confirmed
by Niemeier (9). Also, EDTA has been shown to
decrease the acute lethality from a single injec-
tion of cadmium (10-13). However, EDTA has
also been demonstrated to increase the nephro-
toxicity of cadmium after repeated exposure in
rabbits (10). Dalhamn and Friberg (14) presented
evidence that a similar unfavorable effect ofBAL
upon cadmium toxicity can be observed during
prolonged exposure. Ibbias et al. (15) showedthat
prophylactic treatment with BAL had a deleteri-
ous effect upon mice exposed to cadmium chloride
dust by inhalation. However, when BAL was
given promptly after exposure to the cadmium
dust, in an optimal course ofrepeated injections,
it could reduce the mortality considerably. Also,
BAL increased the cadmium content of the kid-
neys, but this seems not to have been of impor-
tance for mortality orpathological changes, as no
renal pathology was observed following BAL
treatment ofmice poisonedby inhaling cadmium.
The experiments by Ibbias et al. were performed
with an aerosol of CdCl2, an exposure situation
less common in practice than exposure to CdO
aerosol (cadmium fume). This latter exposure
type was used in experiments by MacFarland
(16), who showed that BAL treatment after expo-
sure could considerably reduce the mortality.
That chelating agents such as hydroxyethylene-
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diaminetriacetic acid (HEDTA) and diethylene-
triaminepentaacetic acid (DTPA) had a preven.-
tive effect upon acute cadmium toxicity and that
they decreased the uptake of cadmium in the
kidneys was reported by Eybl, Sykora and Mertl
(11). Similar observations were made by Chati-
lena and Klaassen (12).
A decreased effectiveness of chelation therapy
with time after a single injection ofcadmium was
observed by the early authors in the 1940s and
1950s, and these observations have been con-
firmed by recent investigations (13). Recent in-
vestigations led to an explanation for this phe-
nomenon involving the induction of
metallothionein synthesis which hasbeen studied
and discussed in relation to the binding to chelat-
ingagents (13,16). Strongintracellular binding of
cadmium to metallothionein prevents most che-
lating agents from removing it from this natural
chelate. In the in vivo chelation ofcadmium with
BAL and DTPA from rats exposed to cadmium,
considerable decreases in tissue cadmium concen-
tration were achieved both in the liver and the
kidney in relation to untreated controls. In the
animals treated with BAL only, most ofthe cad-
mium was excreted in the feces; this has been
related to an increased biliary excretion of cad-
mium (16).
Chelating agents that are used in detergents
have been investigated in relation to cadmium
toxicity. Both nitrilotriacetic acid (NTA) and so-
dium tripolyphosphate (STPP) increase the acute
toxicity of cadmium after subcutaneous injection
(17,18) but have no effect on renal long-term
toxicity of cadmium by the oral route in mice
(17,19).
One problem with many ofthe recent studies is
that the possibility of kidney damage was not
investigated.
Cadmium Toxicity and the
Influence of Some Chelating
Agents
Basic Flow Scheme ofCadmium
As discussed by Nordberg (20) and Kagi (21) at
this conference, cadmium ispresent as cadmium-
albumin in blood; immediately after exposure,
such cadmium will be taken up preferably by the
liver (Fig. 1). During the first hours after uptake,
cadmium in the liver will not be bound to metal-
lothionein. The synthesis of metallothionein,
however, will be induced, and after 24 hr, cad-
mium will mainly be bound to metallothionein.
Cadmium metallothionein will to a large extent
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FIGURE 1. Scheme offlow ofcadmium in the body demonstrat-
ing the role ofbinding forms in blood and metallothionein
synthesis and degradation.
remain inthe liver, but a small proportion will be
released into the blood and another small propor-
tion will be constantly turned over, whereby non-
metallothionein-bound cadmium will be released,
which will again induce synthesis of new metal-
lothionein, and so on. Cadmium metallothionein
that occurs in blood plasma will be quickly trans-
ported to the kidney, where it is filtered through
the glomeruli and reabsorbed by the proximal
renal tubule. The metallothionein moity will be
broken down by the lysosomes and nonmetal-
lothionein-bound cadmium is released in the tis-
sue. Such cadmium will stimulate renal metal-
lothionein synthesis and there will be a constant
turnover of metallothionein. A majority of renal
cadmium will be bound to metallothionein in a
long-term exposure situation; however, a certain
amount of nonmetallothionein-bound cadmium
will occur, and when this concentration exceeds a
certain level at the sensitive sites in the cell,
toxicity to the renal tubule will occur.
Influence on Acute Effects
It is important to consider the situation with
metallothionein induction, particularly when dis-
cussing the long-term effects of cadmium. How-
ever, in the acute exposure situation (Fig. 2),
metallothionein synthesis has not yet occurred,
and the lethal effects of cadmium injection are
related to liver toxicity. The increased toxicity of
cadmium when injected subcutaneously in combi-
nation with STPP or NTA is related to a quicker
uptake in blood and a higher level of cadmium-
albumin in plasma which is quickly taken up by
the liver. Thus, ahigh concentration ofnonmetal-
lothionein-bound cadmium is obtained in the
liver before metallothionein synthesis has oc-
curred. This leads to an increased livertoxicity.
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FIGURE 2. Scheme illustrating events ofimportance for acute
cadmium toxicity when chelating agents are given simul-
taneously with cadmium.
The increased renal toxicity ofcadmium when
given incombinationwith BALandthebeneficial
influence oneffectsrelatedtoother organs maybe
explained by the removal of cadmium from the
cadmium-albumin complex in blood plasma and
in tissues where the cadmium-BAL complex is
formed instead. This Cd-BAL complex may dis-
place Cd to other tissues than those at the site of
uptake (e.g., lung), and a favorable effect in rela-
tion to effects on the uptake organ may be ob-
served, whereas renal toxicity is a possible side
effect ofthis type ofchelation therapy.
The EDTA-cadmium complex also is stronger
than the cadmium-albumin complex, and a re-
moval from the albumin site to the EDTA com-
plex will take place. The cadmium-EDTA com-
plex will pass through the kidney into the urine.
A small amount of cadmium will be released in
thekidney,buttoxicconcentrations willnot occur
in acute cadmium poisoning, when relatively
small amounts ofcadmium areoperating (in rela-
tion to the amounts involved in chronic renal
cadmium damage). This explains the favorable
effects of EDTA treatment in acute cadmium in-
toxication.
The situation with regard to long-term cad-
mium exposure is different due to the involvment
ofmetallothionein, which, as has been discussed
previously during this conference, is the most
stable chelating agent internally formed in the
body.
Influence ofSTPP on Chronic
Cadmium Toxicity
When cadmium is combined with sodium tripo-
lyphosphate (STPP), cadmium tripolyphosphate
is formed, which quickly releases its cadmium to
cadmium albumin in blood plasma (Fig. 3). An
increased concentration ofcadmium albuminwill
thus momentarily be formed, and a quicker up-
take will occur in the liver. However, the total
amount transferred will be approximately the
same as without the chelating agent, and since
the liver is not the critical organ in long-term
exposure when relatively small amounts of non-
metallothionein-bound cadmium are operating,
toxic liver concentrations ofnonmetallothionein-
bound cadmium will not arise. Cadmium will be
released in the same way from the liver to the
kidney as without the chelating agent, and no
effect on the renal toxicity should be expected.
This is also what has been observed in actual
long-term experiments.
Flow Scheme ofCadmium-BAL
WhenitcomestoBAL, thecadmium-BAL com-
plex, like BAL can move more freely through the
cell membranes than cadmium-albumin (Fig. 4).
The Cd-BAL complex also has been shown to be
more readily excreted in bile than non-BAL-
bound cadmium. Cadmium-BAL is probably
more stable and more readily formed than cad-
mium-albumin, and BAL will thus probably dis-
place cadmium from cadmium-albumin and
thereby decrease the influx of cadmium into the
liverbut may increase the influx into the kidney.
Ifsufficient amounts of BAL are not provided to
the kidney at all times, the cadmium-BAL com-
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FIGURE 3. Scheme illustrating events taking place when
cadmium and STPP are given in a long-term exposure
situation.
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plex may be broken down and add to the nonme-
tallothionein-bound cadmium in the kidney. If a
borderline amount of this type of cadmium is
already present in the kidney, the cadmium re-
leased from BAL may elevate the concentration
above the critical concentration, and kidney dam-
age may occur. This mechanism, which admit-
tedly is somewhat hypothetical, would fit with
observations of an increased renal toxicity when
cadmium is given together with BAL in repeated
injections. However, if cadmium-albumin is not
present in plasma in any appreciable amount,
BAL may have a beneficial effect in providing a
means for increased excretion of cadmium from
the liver. The effects ofBAL wouldthusto a large
extent be dependent on whether ongoing expo-
sureto cadmium ormobilization ofcadmiumfrom
absorption sites like the lung is taking place.
When this is not the case, it may be that benefi-
cial effects ofBAL canbe expected. However, this
should be demonstrated in experiments where
kidney damage hasbeeninduced. No suchexperi-
ments have been published as yet.
Flow Scheme ofCa um-EDTA
The cadmium-EDTA complex may be excreted
more readily in the urine and thus EDTA injec-
tion may decrease renal concentrations of cad-
mium (Fig. 5). However, an increased renal toxic-
itymaystillbepossibleifEDTAisnotprovided in
sufficient amounts at all times to keep up the
cadmium-EDTA complex, so that no cadmium is
released in the kidney from the cadmium-EDTA
complex. If such release occurs, the already bor-
derline toxic concentration of nonmetallothio-
nein-boundcadmiumthat maybepresentinlong-
term cadmium exposure may be increased. The
critical concentration for nonmetallothionein-
bound cadmium may thus be exceeded, and renal
toxicity may occur. An alternative explanation
for such renal toxicity may be that cadmium-
EDTA is morereadily transferred to.the sensitive
siteswhere cadmiummaybereleasedfrom EDTA
andbound to the sensitive receptor.
Summary
In summary, explanatory schemes concerning
effects ofcadmium in combinationwith acute and
long-term toxicity have been presented as to ac-
commodate asfar aspossible thepublished obser-
vations concerning such effects. It is important in
the future that additional experimental research
be made as to confirm or reject the hypothetical
schemes proposed here. Particularly the possibil-
ity of a beneficial effect of chelation therapy on
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FIGURE 4. Scheme illustrating the flow of cadmium when
BAL is given in repeatedly cadmium-exposed animals or
humans.
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FIGURE 5. Scheme illustrating the flow of cadmium when
EDTA is given to animals (or humans) repeatedly exposed
to cadmium.
renal toxicity needs experimental confirmation.
No firm predictions with regard to the possibility
for such chelation therapy can be made at the
present time even if long-term treatment with
BAL and DTPA has shown favorable influence on
organ concentrations ofcadmium.
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